2022
Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue
Liu T, Dogan I, Rothe M, Kunz J, Knauf F, Gollasch M, Luft F, Gollasch B. Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue. Prostaglandins Leukotrienes And Essential Fatty Acids 2022, 181: 102453. PMID: 35633593, DOI: 10.1016/j.plefa.2022.102453.Peer-Reviewed Original ResearchConceptsRed blood cellsHD treatmentHemodialysis treatmentEnd-stage renal disease patientsHydroxyeicosatetraenoic acidHydroxyeicosapentaenoic acidSingle hemodialysis treatmentChronic kidney diseaseRenal disease patientsRenal replacement therapyFatty acid statusVenous blood samplesHydroxydocosahexaenoic acidEpoxy fatty acidsCause of mortalityLOX pathwayRenal failureFatty acidsKidney diseaseDisease patientsVenous bloodCardiovascular functionAcid statusArteriovenous differenceCardiovascular disease
2013
Dabigatran and Kidney Disease: A Bad Combination
Knauf F, Chaknos CM, Berns JS, Perazella MA. Dabigatran and Kidney Disease: A Bad Combination. Clinical Journal Of The American Society Of Nephrology 2013, 8: 1591-1597. PMID: 23868901, PMCID: PMC3805067, DOI: 10.2215/cjn.01260213.Peer-Reviewed Original ResearchConceptsAnticoagulant effectPharmacokinetic profileOral direct thrombin inhibitorContinuous renal replacement therapyRoutine laboratory monitoringSerious bleeding eventsHigh bleeding riskReduced kidney functionRenal replacement therapyDirect thrombin inhibitorDrug Administration approvalLaboratory monitoring testsBleeding eventsBleeding riskSerious bleedingThromboembolic complicationsDose adjustmentHemodialysis cathetersKidney functionKidney diseaseReplacement therapyLaboratory monitoringAdministration approvalClinical indicationsDrug levels